No-effect Level Research Articles

Workplace exposure to nanoparticles and the application of provisional nanoreference values in times of uncertain risks

Nano reference values (NRVs) for occupational use of nanomaterials were tested as provisional substitute for Occupational Exposure Limits (OELs). NRVs can be used as provisional limit values until Health-Based OELs or derived no-effect levels (DNEL) become available. NRVs were defined for 8 h periods (time weighted average) and for short-term exposure periods (15 min-time weighted average). To assess the usefulness of these NRVs, airborne number concentrations of nanoparticles (NPs) in the workplace environment were measured during paint manufacturing, electroplating, light equipment manufacturing, non-reflective glass production, production of pigment concentrates and car refinishing. Activities monitored were handling of solid engineered NPs (ENP), abrasion, spraying and heating during occupational use of nanomaterials (containing ENPs) and machining nanosurfaces. The measured concentrations are often presumed to contain ENPs as well as process-generated NPs (PGNP). The PGNP are found to be a significant source for potential exposure and cannot be ignored in risk assessment. Levels of NPs identified in workplace air were up to several millions of nanoparticles/cm3. Conventional components in paint manufacturing like CaCO3 and talc may contain a substantial amount of nanosized particulates giving rise to airborne nanoparticle concentrations. It is argued that risk assessments carried out for e.g. paint manufacturing processes using conventional non-nano components should take into account potential nanoparticle emissions as well. The concentrations measured were compared with particle-based NRVs and with mass-based values that have also been proposed for workers protection. It is concluded that NRVs can be used for risk management for handling or processing of nanomaterials at workplaces provided that the scope of NRVs is not limited to ENPs only, but extended to the exposure to process-generated NPs as well.

Studies on the Toxicological Profile of the Local Anaesthetic Articaine

The toxicity of articaine (CAS 23964-58-1) and of a respective preparation (Septanest SP; 4% articaine HCl and epinephrine 1: 100,000) was examined in in vitro and in vivo experiments. The following endpoints were examined: repeated dose toxicity, reproduction toxicity, mutagenic potential and local tolerance. Repeated s.c. administration of articaine HCl in rats and dogs demonstrated no pathomorphological systemic changes even at systemically toxic doses. The no-effect level (NOEL) was 25 mg articaine HCl/kg b.w./day s.c. for the rat and 40 mg articaine HCl/kg b.w./day s.c. for the dog. Reproduction studies were performed in rats and rabbits at doses up to more than 10 times the maximum recommended human dose of 7 mg articaine HCl/kg b.w. and revealed no evidence of harm to the foetus or to other aspects of reproduction, even at doses toxic to the parental animals. Four standard in vitro and in vivo mutagenicity studies have shown no mutagenic potential up to cytotoxic concentrations or up to the maximum tolerated dose level. The local tolerance of articaine HCl was good to very good. The preclinical data indicate that articaine HCl does not possess any relevant side-effects or gross toxicity and can be considered a safe local anaesthetic.

Developmental toxicity studies of the quinolone antibacterial agent irloxacin in rats and rabbits.

Embryotoxicity studies on irloxacin (6-fluorine-7-(pyrrol-1-yl)-1-ethyl-1,4-dihydro-4-oxo-quinolone-3-carboxylic acid, CAS-91524-15-1), a new fluoroquinolone antibacterial agent, were performed in rats and rabbits. Oral administration of irloxacin during the fetal period of organogenesis to pregnant rats and rabbits at dose levels of up to 1000 and 350 mg/kg/d, respectively, elicited no evidence of teratogenicity. During the first days of treatment, transient stasis in body weight increase was observed in rat dams receiving doses of 350 or 1000 mg/kg/d, and reduced food consumption was observed in those receiving 1000 mg/kg/d. Necropsy on day 20 of gestation showed dosage related increase in liver and kidney weights in all rat treated groups. Rabbit dams receiving 350 mg/kg/d showed during the first days of treatment decrease in body weight, and decreased food consumption and faecal output. Also, four females receiving 350 mg/kg/d aborted between days 18 and 20 of gestation. Rat fetuses in the 350 and 1000 mg/kg/d showed decreased body weight, and a decrease in placental weights was observed in the 1000 mg/kg/d group. No retardations or malformations were observed in rat or rabbit fetuses at any tested dose level. For maternal and embryo-fetal effects 100 and 150 mg/kg/d can be considered as the no-effect-level (NOEL) for rats and rabbits, respectively.

Application of human biomonitoring (HBM) of chemical exposure in the characterisation of health risks under REACH

REACH requires health risk management for workers and the general population and introduced the concept of Derived No-Effect Level (DNEL). DNELs must be derived for all substances that are classified as hazardous. In analogy to other health-risk based guidance values, such as reference doses (RfDs) and tolerable daily intakes (TDIs), risk to health is considered negligible if the actual exposure is less than the DNEL. Exposure assessment is relatively simple for occupational situations but more complex for the general public, in which exposure may occur via multiple pathways, routes, and media. For such complex or partially defined exposure scenarios, human biomonitoring (HBM) gives a snapshot of the internal or absorbed dose of a chemical and is often the most reliable exposure assessment methodology. For human risk management, HBM data can be interpreted using the recently developed concept of Biomonitoring Equivalents (BEs). Basically, a BE translates an established reference value into a biomarker concentration using toxicokinetic data. If the results of an exposure assessment using HBM indicate that the levels measured are below the DNEL-based BE (BE(DNEL)), it would indicate that the combined exposure via all potential exposure routes is unlikely to pose a risk to human health and that health risk management measures might not be needed. Hence, BEs do not challenge existing risk assessments but rather build upon them to help risk management, the ultimate goal of any risk assessment. A challenge in implementing this approach forms the limited availability of toxicokinetic information for many substances. However, methodologies such as generic physiologically based toxicokinetic models, which allow estimation of biomarker concentrations based on physicochemical properties, are being developed for less data-rich chemicals. Acceptance of the use of BE by regulatory authorities will allow initial screening of population exposure to chemicals to identify those chemicals requiring more detailed risk and exposure assessment, assisting in priority setting and ultimately leading to improved product stewardship and risk management.

Neurobehavioral Effects of Acute Exposure to Isoparaffinic and Cycloparaffinic Hydrocarbons

This article reports neurobehavioral tests in rats with C5-C11 isoparaffinic and cycloparaffinic hydrocarbons. Testing, conducted shortly after exposure, evaluated the effects in several domains including clinical effects, motor activity, functional observations, and visual discrimination performance. Isopentane and cyclopentane did not produce any evidence of acute central nervous system (CNS) effects at levels up to 20 000 mg/m(3). A C(6)/C(7) mixed cycloparaffinic solvent produced minor, reversible changes in latency to response in visual discrimination testing at 14 000 mg/m(3); the no-effect level was 4200 mg/m(3). A C(8) isoparaffin produced no effects at 14 000 mg/m(3), the highest level tested. A C(9)/C(11) isoparaffinic solvent produced minor acute CNS effects at 5000 mg/m(3), with 1500 mg/m(3) as the no-effect level. A C(10) cycloparaffinic solvent did not produce any statistically significant CNS effects at 5000 mg/m(3). These studies were designed to provide data that may be useful in setting occupational exposure limits for C5-C11 isoparaffinic and cycloparaffinic hydrocarbons.

Comparing the safety margins in the European indicative occupational exposure limits and the derived no-effect levels under reach

The new European Union (EU) REACH legislation requires Derived No-Effect Levels (DNEL) to be calculated for substances produced in quantities above 10 tonnes/year. Workers are one population that these DNELs are to protect. Meanwhile, the setting of occupational exposure limits (OEL) continues both at the member state and the EU level. Health-based OELs are proposed by the Commission's Scientific Committee on OELs (SCOEL) and eventually result in Indicative OEL Values (IOELV) in EU Directives. According to REACH, IOELVs may under some circumstances be used as worker-DNELs. On the other hand, worker-DNELs will be derived for several thousand substances, far more than the roughly 100 substances for which IOELVs have been established. Thus, the procedure to set health-based OELs may become influential on that of DNELs and vice versa. This study presents a comparison of the safety margins of 88 SCOEL recommendations with those of the corresponding worker-DNELs, derived according to the REACH guidance document. Overall, the REACH safety margins were approximately six times higher than those derived from the SCOEL documentation but varied widely with REACH/SCOEL ratios ranging by two orders of magnitude, from 0.3 to 58. It was also found that the REACH guidance document, although encompassing detailed advice on many issues, including default assessment factors for species and route extrapolation, gives no quantitative guidance on when and how to depart from defaults.

Approaches for establishing human health no effect levels for engineered nanomaterials

Current Technical Guidance Documents for preparing risk assessments, like the guidance for the implementation of REACH, have limited focus on chemical substances in the particulate form and generally do not focus on substances in the nanoform.Within the ENRHES project a comprehensive and critical scientific review of publicly available health and safety information on four types of nanoparticles was performed. Based on the identified exposure and hazard data, basic human health risk assessment appraisals were carried out for fullerenes, carbon nanotubes, nano-silver and nano-titanium dioxide. These risk assessment appraisals followed the structure of a regulatory risk assessment and if possible and relevant, it was attempted to derive indicative human no-effect levels from key studies by applying assessment factors as suggested in the technical guidance document for REACH. These assessment factors address differences and uncertainty related to exposure features between test animals and humans (time, respiratory volume), other interspecies and intraspecies differences and factors for extrapolation to chronic duration. If required, the severity of effects and the quality of the database can be addressed by additional factors.Recently other procedures for deriving human no-effect levels have been published and these are compared to the ENRHES basic risk assessment appraisals. The main differences were observed in relation to evaluating the differences in animal and human exposure situations and interspecies differences, and in applying assessment factors for intraspecies differences for local effects. The applicability of the REACH guidance for nanomaterials is currently being investigated for possible adaptations, considering the specific behaviour and mode of action of nanomaterials.

A Molecular and Phenotypic Integrative Approach to Identify a No-Effect Dose Level for Antiandrogen-Induced Testicular Toxicity

The safety assessment of chemicals for humans relies on identifying no-observed adverse effect levels (NOAELs) in animal toxicity studies using standard methods. With the advent of high information content technologies, especially microarrays, it is pertinent to determine the impact of molecular data on the NOAELs. Consequently, we conducted an integrative study to identify a no-transcriptomic effect dose using microarray analyses coupled with quantitative reverse transcriptase PCR (RT-qPCR) and determined how this correlated with the NOAEL. We assessed the testicular effects of the antiandrogen, flutamide (FM), in a rat 28-day toxicity study using doses of 0.2-30 mg/kg/day. Plasma testosterone levels and testicular histopathology indicated a NOAEL of 1 mg/kg/day. A no-effect dose of 0.2 mg/kg/day was established based on molecular data relevant to the phenotypic changes. We observed differential gene expression starting from 1 mg/kg/day and a deregulation of more than 1500 genes at 30 mg/kg/day. Dose-related changes were identified for the major pathways (e.g., fatty acid metabolism) associated with the testicular lesion (Leydig cell hyperplasia) that were confirmed by RT-qPCR. These data, along with protein accumulation profiles and FM metabolite concentrations in testis, supported the no-effect dose of 0.2 mg/kg/day. Furthermore, the microarray data indicated a dose-dependent change in the fatty acid catabolism pathway, a biological process described for the first time to be affected by FM in testicular tissue. In conclusion, the present data indicate the existence of a transcriptomic threshold, which must be exceeded to progress from a normal state to an adaptative state and subsequently to adverse toxicity.

Abstract 5553: Low-dose carcinogenicity of 2-amino-3-methylimidazo[4,5-f]quinoline in rats: Evidence for the existence of no-effect levels and a mechanism involving p21Cip/WAF1

Abstract The carcinogenicity of the low amounts of genotoxic carcinogens present in food is of pressing concern. The purpose of the present study was to determine the carcinogenicity of low doses of the dietary genotoxic carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and to investigate mechanisms by which IQ exerts its carcinogenic effects. A total of 1595 male F344 rats were divided into 7 groups and administered IQ at doses of 0, 0.001, 0.01, 0.1, 1, 10 and 100 ppm in the diet for 16 weeks. We found that IQ doses of 1 ppm and below did not induce preneoplastic lesions in either the liver or the colon, while IQ doses of 10 and 100 ppm induced preneoplastic lesions in both these organs. These results demonstrate the presence of no effect levels of IQ for both liver and colon carcinogenicity in rats and indicate that the dose-response relationship for IQ carcinogenicity is nonlinear. The finding that p21Cip/WAF1 was significantly induced in the liver at doses well below those required for IQ mediated carcinogenic effects, suggests that induction of p21Cip/WAF1 is one of the mechanisms responsible for the observed no-effect of low doses of IQ. Furthermore, IQ administration caused significant induction of CYP1A2 at doses of 0.01 to 10 ppm, but administration of 100 ppm IQ induced CYP1A1 rather than CYP1A2. This result indicates the importance of dosage when interpreting data on the carcinogenicity and metabolic activation of IQ. Overall, our results argue for the existence of a practical carcinogenic threshold for this genotoxic compound. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5553. doi:10.1158/1538-7445.AM2011-5553

Analysis of currently available data for characterising the risk of engineered nanomaterials to the environment and human health — Lessons learned from four case studies

Production volumes and the use of engineered nanomaterials in many innovative products are continuously increasing, however little is known about their potential risk for the environment and human health. We have reviewed publicly available hazard and exposure data for both, the environment and human health and attempted to carry out a basic risk assessment appraisal for four types of nanomaterials: fullerenes, carbon nanotubes, metals, and metal oxides (ENRHES project 2009 1 1 Engineered Nanoparticles — Review of Health and Environmental Safety (ENRHES project) 2009 EU 7th research framework programme http://ihcp.jrc.ec.europa.eu/whats-new/enhres-final-report. ). This paper presents a summary of the results of the basic environmental and human health risk assessments of these case studies, highlighting the cross cutting issues and conclusions about fate and behaviour, exposure, hazard and methodological considerations. The risk assessment methodology being the basis for our case studies was that of a regulatory risk assessment under REACH ( ECHA, 2008 2 2 ECHA (European Chemicals Agency), 2008. REACH Guidance on Information Requirements and Chemicals Safety Assessment. http://guidance.echa.europa.eu/guidance_en.htm. ), with modifications to adapt to the limited available data. If possible, environmental no-effect concentrations and human no-effect levels were established from relevant studies by applying assessment factors in line with the REACH guidance and compared to available exposure data to discuss possible risks. When the data did not allow a quantitative assessment, the risk was assessed qualitatively, e.g. for the environment by evaluating the information in the literature to describe the potential to enter the environment and to reach the potential ecological targets. Results indicate that the main risk for the environment is expected from metals and metal oxides, especially for algae and Daphnia, due to exposure to both, particles and ions. The main risks for human health may arise from chronic occupational inhalation exposure, especially during the activities of high particle release and uncontrolled exposure. The information on consumer and environmental exposure of humans is too scarce to attempt a quantitative risk characterisation. It is recognised that the currently available database for both, hazard and exposure is limited and there are high uncertainties in any conclusion on a possible risk. The results should therefore not be used for any regulatory decision making. Likewise, it is recognised that the REACH guidance was developed without considering the specific behaviour and the mode of action of nanomaterials and further work in the generation of data but also in the development of methodologies is required.

A Quantitative Comparison of the Safety Margins in the European Indicative Occupational Exposure Limits and the Derived No-Effect Levels for Workers under REACH

The new European Union (EU) REACH legislation requires derived no-effect levels (DNELs) to be calculated for substances produced in quantities above 10 tonnes/year. Meanwhile, the setting of occupational exposure limits (OELs) continues both at the member state and the EU levels. According to REACH, indicative OEL values (IOELVs) from the Commission may under some circumstances be used as worker-DNELs. On the other hand, worker-DNELs will be derived for several thousand substances, far more than the approximately 100 substances for which IOELVs have been established. Thus, the procedure to set health-based OELs may become influential on that of DNELs and vice versa. In this study, we compare the safety margins of 88 Scientific Committee on OELs (SCOEL) recommendations with those of the corresponding worker-DNELs, derived according to the default approach as described in the REACH guidance document. Overall, the REACH safety margins were approximately six times higher than those derived from the SCOEL documentation but varied widely with REACH/SCOEL safety margin ratios ranging by two orders of magnitude, from 0.3 to 58 (n = 88). The discrepancies may create confusion in terms of legal compliance, risk management, and risk communication. We also found that the REACH guidance document, although encompassing detailed advice on many issues, including default assessment factors for species and route extrapolation, gives little quantitative guidance on when and how to depart from defaults.

Assessment of subclinical, toxicant-induced hepatic gene expression profiles after low-dose, short-term exposures in mice

Gene expression profiling that examines critical, toxicologically-relevant gene and signal-response pathways promises to improve risk assessment and safety evaluation of low-dose chemical exposures. As an approach to achieving this goal, mechanistic interpretations based upon gene expression changes that are determinants of adverse toxicological outcomes were applied to the analysis of low-dose gene expression profiles. RNA for expression profiling was obtained from mice given short-term gavage exposures to diminishing doses of four toxicants: 3,3′,4,4′,5-pentachlorobiphenyl (PCB126), phenobarbital (PB), isoproterenol (IPR), and lead acetate (PbAc). Lowest doses were below the no-observable effects levels established using standard clinical toxicology parameters. Hepatic gene expression profiles were analyzed using a custom, focused oligonucleotide DNA microarray, the HC ToxArray™, containing toxin-responsive and toxicologically-determinant genes. Expression data were compared to changes in conventional clinical chemistry parameters and drug metabolism activities. PCB126 and PB demonstrated a dose-dependent correlation between minimal changes in biochemical markers, hepatic metabolism and induction of gene expression profiles. PbAc exposure gave a small adaptive profile at the highest dose. IPR- and PCB126-induced changes were detected at doses below those required to alter the traditional biochemical endpoints and included genes with causal roles in hepatic toxicity, insulin resistance, atherosclerosis, angiogenesis and hypertension. Likely adverse phenotypic consequences resulting from expression changes lead to assignments of “Lowest Observed Adverse Transcriptional Expression Levels” (LOATEL) for each agent. These results support the suggestion that altered expression profiles of genes contributing to toxicologically-relevant pathways provide useful tools for reducing uncertainty in establishing no-effect levels and for designing longer-term toxicity studies.

Industry–Contract Research Organization Pathology Interactions

This article provides observations on the features of sponsor–contract research organization communication that will achieve the best quality pathology report based on our collective experience. Information on the test article and any anticipated findings should be provided, and initial slide examination should be done with knowledge of treatment group (but may be followed by blinded review of target tissues to determine no-effect levels). Only a pathologist should write or revise the pathology report or the pathology section of the overall study report. To address concerns related to undue sponsor influence, comments by sponsors should be presented as suggestions rather than directives. Adversity should be defined for each finding by the study pathologist, but the no-observed adverse effect level should not be discussed in the pathology report. Board-certified pathologists are recommended, but are not essential. Sponsors that have a particular format or report preferences should make them known well in advance. Histologic processing “to glass” of protocol-specified tissues from all dosage groups is recommended for rapid evaluation of target tissues. Telepathology is beneficial in certain situations, but it is usually more efficient for the study pathologist and reviewing pathologist to be in the same physical location to review differences of opinion and reach a consensus.

Neurobehavioral Effects of Acute Exposure to Normal (n-) Paraffins

This article reports the results of neurobehavioral tests on C(5)-C(10) normal paraffinic constituents (n-paraffins). Shortly after exposure, effects were evaluated in several domains including clinical effects, motor activity, functional observations, and visual discrimination performance. The representative C(5) n-paraffin, n-pentane, did not produce any evidence of acute central nervous system (CNS) effects at levels up to 20 000 mg/m(3). Similarly, there was no compelling evidence that n-octane (C(8)) produced CNS effects at 14 000 mg/m(3), the highest concentration tested. n-decane (C(10)) produced minor, reversible acute CNS effects at 5000 mg/m(3), with 1500 mg/m(3) as the no-effect level. Consistent with literature data, there seemed to be a relationship between increasing molecular weight up to C(10) and acute CNS effects. However, the CNS effects were reversible. Repeated exposures did not provide evidence of metabolic induction.

Biomarkers of Chlorpyrifos Exposure and Effect in Egyptian Cotton Field Workers

BackgroundChlorpyrifos (CPF), a widely used organophosphorus pesticide (OP), is metabolized to CPF-oxon, a potent cholinesterase (ChE) inhibitor, and trichloro-2-pyridinol (TCPy). Urinary TCPy is often used as a biomarker for CPF exposure, whereas blood ChE activity is considered an indicator of CPF toxicity. However, whether these biomarkers are dose related has not been studied extensively in populations with repeated daily OP exposures.ObjectiveWe sought to determine the relationship between blood ChE and urinary TCPy during repeated occupational exposures to CPF.MethodsDaily urine samples and weekly blood samples were collected from pesticide workers (n = 38) in Menoufia Governorate, Egypt, before, during, and after 9–17 consecutive days of CPF application to cotton fields. We compared blood butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE) activities with the respective urinary TCPy concentrations in each worker.ResultsAverage TCPy levels during the middle of a 1- to 2-week CPF application period were significantly higher in pesticide applicators (6,437 μg/g creatinine) than in technicians (184 μg/g) and engineers (157 μg/g), both of whom are involved in supervising the application process. We observed a statistically significant inverse correlation between urinary TCPy and blood BuChE and AChE activities. The no-effect level (or inflection point) of the exposure–effect relationships has an average urinary TCPy level of 114 μg/g creatinine for BuChE and 3,161 μg/g creatinine for AChE.ConclusionsOur findings demonstrate a dose–effect relationship between urinary TCPy and both plasma BuChE and red blood cell AChE in humans exposed occupationally to CPF. These findings will contribute to future risk assessment efforts for CPF exposure.

Juvenile toxicity assessment of open-acid lovastatin in rats

Lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, reduces de novo cholesterol biosynthesis primarily in the liver. Since cholesterol is a major component of brain myelin and peak periods of brain myelination occurs after birth, this study was designed to encompass this period in rats and evaluate the potential neurotoxic effects. The pharmacologically active, open-acid form of lovastatin was administered to groups of 50 Sprague-Dawley rats per sex subcutaneously once daily at dose levels of 0 (vehicle), 2.5, 5, or 10 mg/kg/day beginning on postnatal day 4 and continuing until termination on postnatal day 41 to 51. Physical signs and body weights were monitored during the study. Animals were assessed in a battery of behavioral tests, and at termination a set of animals were examined for gross and histological changes. There were no test article-related deaths, physical signs, or effects on preweaning and postweaning body weights during the study. In the behavior tests there were no test article-related effects in the passive avoidance, auditory startle habituation, open-field motor activity, or FOB. No test article-related postmortem findings were observed, including brain weights and histomorphology of brain, spinal cord, eye, optic nerve, or peripheral nerve. Based on these results, the no-effect level for general and neurobehavioral toxicity in neonatal rats was ≥10 mg/kg/day for open-acid lovastatin.

Poorly soluble particulates: Searching for a unifying denominator of nanoparticles and fine particles for DNEL estimation

Under the new European chemicals regulation, REACH (Registration, Evaluation, Authorization and Restriction of Chemicals) a Derived No-Effect Level (DNEL), i.e., the level of exposure above which humans should not be exposed, is defined. The focus of this paper is to develop a weight-of-evidence-based DNEL-approach for inhaled poorly soluble particles. Despite the common mode of action of inhaled insoluble, spherical particulate matter (PM), a unifying, most appropriate metric conferring pulmonary biopersistence and toxicity has yet not been demonstrated. Nonetheless, there is compelling evidence from repeated rat inhalation exposure studies suggesting that the particle displacement volume is the most prominent unifying denominator linking the pulmonary retained dose with toxicity. Procedures were developed to analyze and model the pulmonary toxicokinetics from short-term to long-term exposure. Six different types of poorly soluble nano- to submicron PMs were compared: ultrafine and pigmentary TiO 2, synthetic iron oxide (Fe 3O 4, magnetite), two aluminum oxyhydroxides (AlOOH, Boehmite) with primary isometric particles approximately of either 10 or 40 nm, and MWCNT. The specific agglomerate densities of these materials ranged from 0.1 g/cm 3 (MWCNT) to 5 g/cm 3 (Fe 3O 4). Along with all PM, due to their long retention half-times and associated biopersistence in the lung, even short-term inhalation studies may require postexposure periods of at least 3 months to reveal PM-specific dispositional and toxicological characteristics. This analysis provides strong evidence that pulmonary toxicity (sustained inflammation) is dependent on the volume-based cumulative lung exposure dose. Lung toxicity, evidenced by PMN in BAL occurred at lung doses exceeding 10-times the overload threshold. Furthermore, the conclusion is supported that repeated inhalation studies on rats should utilize an experimental window of cumulative volume loads of respirable PM in the range of 1 μl/lung (no-adverse-effect range); however, not exceeding ≈10 μl/lung that would lead to retention half-times increasing 1 year. This can be targeted best by computational toxicology, i.e., the modeling of particle deposition and lung retention biokinetics during the exposure and recovery periods. Inhalation studies exceeding that threshold volume may lead to meaningless findings difficult to extrapolate to any real-life scenario. In summary, this analysis supports a volume-based generic mass concentration of 0.5 μl PM respirable/m 3 × agglomerate density, independent on nano- or submicron-sized properties, as a generic no-adverse effect level in both rats and humans.

Low‐dose carcinogenicity of 2‐amino‐3‐methylimidazo[4,5‐f ]quinoline in rats: Evidence for the existence of no‐effect levels and a mechanism involving p21Cip / WAF1

The carcinogenicity of the low amounts of genotoxic carcinogens present in food is of pressing concern. The purpose of the present study was to determine the carcinogenicity of low doses of the dietary genotoxic carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and to investigate mechanisms by which IQ exerts its carcinogenic effects. A total of 1595 male F344 rats were divided into seven groups and administered with IQ at doses of 0, 0.001, 0.01, 0.1, 1, 10 and 100 p.p.m. in the diet for 16 weeks. We found that IQ doses of 1 p.p.m. and below did not induce preneoplastic lesions in either the liver or the colon, while IQ doses of 10 and 100 p.p.m. induced preneoplastic lesions in both of these organs. These results demonstrate the presence of no-effect levels of IQ for both liver and colon carcinogenicity in rats. The finding that p21(Cip/WAF1) was significantly induced in the liver at doses well below those required for IQ mediated carcinogenic effects suggests that induction of p21(Cip/WAF1) is one of the mechanisms responsible for the observed no-effect of low doses of IQ. Furthermore, IQ administration caused significant induction of CYP1A2 at doses of 0.01-10 p.p.m., but administration of 100 p.p.m. IQ induced CYP1A1 rather than CYP1A2. This result indicates the importance of dosage when interpreting data on the carcinogenicity and metabolic activation of IQ. Overall, our results suggest the existence of no-effect levels for the carcinogenicity of this genotoxic compound.

Human biomonitoring as a pragmatic tool to support health risk management of chemicals – Examples under the EU REACH programme

REACH requires health risk management for workers and the general population and introduced the concept of Derived No-Effect Level (DNEL). DNELs must be derived for all substances that are classified as health hazards. As with analogues to other health-risk based guidance values, such as reference doses (RfDs) and tolerable daily intakes (TDIs), risk to health is considered negligible if the actual exposure is less than the DNEL. Exposure assessment is relatively simple for occupational situations but more complex for the general public, in which exposure may occur via multiple pathways, routes, and media. For such complex or partially defined exposure scenarios, human biomonitoring gives a snapshot of internal or absorbed dose of a chemical and is often the most reliable exposure assessment methodology as it integrates exposures from all routes. For human risk management human biomonitoring data can be interpreted using the recently developed concept of Biomonitoring Equivalents (BE). Basically, a BE translates an established reference value into a biomarker concentration using toxicokinetic data. If the results of an exposure assessment using human biomonitoring indicate that the levels measured are below the DNEL-based BE (BEDNEL), it would indicate that the combined exposure via all potential exposure routes is unlikely to pose a risk to human health and that health risk management measures might not be needed. Hence, BEs do not challenge existing risk assessments but rather build upon them to help risk management, the ultimate goal of any risk assessment. A challenge in implementing this approach forms the limited availability of toxicokinetic information for many substances. However, methodologies such as generic physiologically-based toxicokinetic models, which allow estimation of biomarker concentrations based on physicochemical properties, are being developed for less data-rich chemicals. Use of BE by regulatory authorities will allow initial screening of population exposure to chemicals to identify those chemicals requiring more detailed risk and exposure assessment, assisting in priority setting and ultimately leading to improved product stewardship and risk management.

Comparison of methods for analysis of functional observation battery (FOB) data

Introduction: Different methods for the analysis of behavioral observation data were compared to evaluate how the interpretation of a data set may depend on the analysis method employed. Methods: Three methods of analysis were used to evaluate the same four sets of rodent behavioral FOB data: (1) evaluation by a trained behavioral toxicologist (ToxRev); (2) Kruskal–Wallis statistical analysis of variance for nonparametric data followed by Wilcoxon pairwise tests (KW) and (3) Cochran–Mantel–Haenszel statistical analysis of variance for nonparametric data followed by Wilcoxon pairwise tests (CMH). The FOB consisted of 9 behavioral, 10 neurologic and 7 autonomic parameters that were evaluated following administration of either vehicle or diazepam (1 or 4mg/kg; 1, 2 or 5mg/kg) to male and female rats. The chosen data sets were labeled A, B, C and D. The outcomes of the three analysis methods were compared to identify similarities and differences. Results: ToxRev, KW and CMH analyses were in agreement in determining the no-effect level (NEL) for each data set. All methods were also in agreement calling the fewest FOB parameters in data set C, and correctly identifying the most effects in the behavior functional domain in each data set. The 3 methods were also in agreement in correctly not calling parameters such as convulsion. No single analysis method stood out as remarkably more permissive in identifying effects of diazepam on FOB parameters, although CMH appeared to be the most conservative method, identifying the fewest effects across all data sets. Discussion: Factors contributing to these patterns of outcome are discussed, including variability within and between dose groups. ToxRev, KW and CMH are all viable methods for evaluating FOB-type data, however minor differences in a study's outcome using these analyses may be dependent upon the method selected.